I N T R O D U C T I O NCardiovascular diseases (CVD) are the leading cause of mortality and admission in hospital for women, accounting for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age in developing countries [1,2]. By contrast, breast cancer accounts for just 3% of all deaths in the female adult population [3].Recent advances in the field of cardiovascular medicine have not led to significant drops in case fatality rates for women, compared to the dramatic reductions achieved for men [4]. Such gender-specific difference in CVD mortality provides additional support for a lack of comparable progress in population-based risk reduction efforts for women [2] and is probably related to a knowledge gap about CVD in women.In this context, several evidences demonstrated significant delays in health care-seeking behaviour, less intensive resource use patterns and longer diagnosis times for women than men. In this context, women are less likely to be referred for coronary angiography and revascularization procedures than men, and referral tends to occur at a later stage in the disease process [5]. Although a lower intensity of care may be, in part, related to a differential clinical history, symptoms profile and acuity of presentation, under-recognition of a cardiovascular involvement in women by caregivers may also be contributory to worsening outcome, especially in women with an established diagnosis of ischaemic heart disease or myocardial infarction [6]. Moreover, pharmacological therapy is hampered by defective evidence, as women are frequently underrepresented in clinical trials and there may be gender
A B S T R A C TMore than a quarter of a million women die each year in the industrialized countries from cardiovascular diseases (CVD), and current projections indicate that this number will continue to rise with our ageing population. Important sex-related differences in the prevalence, presentation, management and outcomes of different CVD have discovered in the last two decades of cardiovascular research. Nevertheless, much evidence supporting contemporary recommendations for testing, prevention and treatment of CVD in women is still extrapolated from studies conducted predominantly in men. The compendium of CVD indicates that current research and strategy development must focus on gender-specific issues to address the societal burden and costs related to these incremental shifts in female gender involvement. Indeed, this significant burden of CVD in women places unique diagnostic, treatment and financial encumbrances on our society that are only further intensified by a lack of public awareness about the disease on the part of patients and clinicians alike. This societal burden of the disease is, in part, related to our poor understanding of genderspecific pathophysiologic differences in the presentation and prognosis of CVD and the paucity of diagnostic and treatment guidelines tailored to phenotypic differences in women. In this, scenario is of outmost importanc...